Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $19.6 million.

  • Agios Pharmaceuticals' Accounts Payables rose 1405.82% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 1405.82%. This contributed to the annual value of $16.6 million for FY2024, which is 7017.38% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Accounts Payables of $19.6 million as of Q3 2025, which was up 1405.82% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Accounts Payables peaked at $51.2 million during Q1 2021, and registered a low of $7.7 million during Q2 2021.
  • Moreover, its 5-year median value for Accounts Payables was $11.6 million (2023), whereas its average is $14.9 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Accounts Payables soared by 17382.26% in 2021, and later tumbled by 7745.0% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Accounts Payables (Quarter) stood at $16.7 million in 2021, then rose by 11.47% to $18.6 million in 2022, then plummeted by 47.46% to $9.8 million in 2023, then soared by 70.17% to $16.6 million in 2024, then grew by 17.48% to $19.6 million in 2025.
  • Its Accounts Payables stands at $19.6 million for Q3 2025, versus $17.5 million for Q2 2025 and $13.7 million for Q1 2025.